Changjiang Securities·2025-09-02 10:43Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Views - The long-term logic of the insurance industry is the improvement of profitability, while the short-term focus is on market beta. As a pure life insurance company with a high equity position, the company shows superior sensitivity and elasticity compared to the life insurance sector, making it a recommended quality beta asset allocation [2][12]. - The essence of life insurance is long-term business operations, and fluctuations in present value due to discount rates are merely short-term volatility that should not be overly emphasized [2]. - The company achieved a PEV valuation of 0.73 times for 2025, maintaining a "Buy" recommendation [2]. Summary by Sections Financial Performance - The company reported a net profit attributable to shareholders of 14.8 billion yuan, a year-on-year increase of 33.5%. The new business value reached 6.18 billion yuan, growing by 58.4% year-on-year [6][12]. - The annualized total investment return rate was 5.9%, up by 1.1 percentage points year-on-year, leading the industry in both absolute value and growth [12]. - The company's premium income was 121.26 billion yuan, an increase of 22.7% year-on-year, with long-term insurance new single premiums growing by 113.1% and periodic new single premiums increasing by 64.9% [12]. Business Quality - The company has shown continuous improvement in business quality, with a decrease in the surrender rate by 0.1 percentage points compared to the same period last year, and improvements in both 13-month and 25-month continuation rates [12]. - The individual insurance and bancassurance channels performed strongly, with individual insurance periodic new single premiums increasing by 70.8% and bancassurance periodic new single premiums growing by 55.4% [12]. Market Position - The company is recommended for its high elasticity and sensitivity in the insurance sector, with a focus on long-term profitability improvement and market beta [2][12].